



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/021,571

12/19/2001

Moses V. Chao

CHAO=11A

9320

1444

7590

12/03/2002

BROWDY AND NEIMARK, P.L.L.C.
624 NINTH STREET, NW
SUITE 300
WASHINGTON, DC 20001-5303

EXAMINER

NICHOLS, CHRISTOPHER J

ART UNIT

PAPER NUMBER

1647

DATE MAILED: 12/03/2002

5

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/021,571

Applicant(s)

CHAO ET AL.

Examiner

Christopher Nichols, Ph.D.

Art Unit

1647

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 15 July 2001.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-34 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) _____ is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claim(s) 1-34 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____.
- 4) ☐ Interview Summary (PTO-413) Paper No(s) _____.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____.

DETAILED ACTION

Election/Restrictions

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1, 2, 5, and 8, (each in part), drawn to an isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 2, classified in class 530, subclass 350, for example.
 - II. Claims 1, 3, 4, 6, 7, and 9 (each in part), drawn to an isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 4, classified in class 530, subclass 350, for example.
 - III. Claims 10-12 and 13 (each in part), drawn to a molecule which contains the antigen-binding portion of an antibody specific for a polypeptide comprising SEQ ID NO: 2, classified in class 530, subclass 388.1, for example.
 - IV. Claims 10-12 and 15 (each in part), drawn to a molecule which contains the antigen-binding portion of an antibody specific for a polypeptide comprising SEQ ID NO: 4, classified in class 530, subclass 388.1, for example.
 - V. Claim 14, drawn to a method for visualizing the growth cone of neurons using an antibody specific for SEQ ID NO: 2, classified in class 435, subclass 7.1, for example.
 - VI. Claim 16, drawn to a method for visualizing the growth cone of neurons using an antibody specific for SEQ ID NO: 4, classified in class 435, subclass 7.1, for example.

Art Unit: 1647

VII. Claims 17-19, 22, 24, 26-30, and 32-34 (each in part) drawn to method for producing an isolated polypeptide comprising an isolated nucleic acid, vectors, and cells comprising the same wherein the nucleic acid comprises SEQ ID NO: 1, classified in class 536, subclass 23.1, for example.

VIII. Claims 17, 20-21, 23, 25-29, and 31-34 (each in part) drawn to method for producing an isolated polypeptide comprising an isolated nucleic acid, vectors, and cells comprising the same wherein the nucleic acid comprises SEQ ID NO: 3, classified in class 536, subclass 23.1, for example.

2. The inventions are distinct, each from the other because of the following reasons:

3. Although there are no provisions under the section for "Relationship of Inventions" in M.P.E.P. § 806.05 for inventive Inventions that are directed to different methods, restriction is deemed to be proper because these methods appear to constitute patentably distinct inventions for the following reasons: Inventions V, VI, VII, and VIII are directed to methods that are distinct both physically and functionally, and are not required one for the other. Invention V requires search and consideration of SEQ ID NO: 2, which is not required by any of the other Inventions. Invention VI requires search and consideration of SEQ ID NO: 4, which is not required by any of the other Inventions. Invention VII requires search and consideration of SEQ ID NO: 1, which is not required by any of the other Inventions. Invention VIII requires search and consideration of SEQ ID NO: 3, which is not required by any of the other Inventions.

4. Although there are no provisions under the section for "Relationship of Invention" in M.P.E.P. § 806.05 for inventive groups that are directed to different products, restriction is

Art Unit: 1647

deemed to be proper because these products constitute patentably distinct inventions for the following reasons. Inventions I, II, III, and IV are directed to products that are distinct both physically and functionally, are not required one for the other, and are therefore patentably distinct. The isolated polypeptide of Invention I is independent and distinct from the products of Inventions II and IV because neither is required to make or use the isolated polypeptide of Invention I. Although the antigen-binding molecule of Invention III can be used to obtain the polypeptide of Invention I it can also be used in materially different methods, such as in various diagnostic (e.g., as a probe in immunoassays or immunochromatography), or therapeutic methods. The isolated polypeptide of Invention II is independent and distinct from the products of Inventions I and III because neither is required to make or use the isolated polypeptide of Invention II. Although the antigen-binding molecule of Invention IV can be used to obtain the polypeptide of Invention II it can also be used in materially different methods, such as in various diagnostic (e.g., as a probe in immunoassays or immunochromatography), or therapeutic methods. The antigen-binding molecule of Invention III is independent and distinct from the products of Inventions II and IV because neither is required to make or use the antigen-binding molecule of Invention III. Although the polypeptide of Invention I can be used to obtain the antigen-binding molecule of Invention III it can also be used in materially different methods, such as in various diagnostic (e.g., isolating receptors), or therapeutic methods. The antigen-binding molecule of Invention IV is independent and distinct from the products of Inventions I and III because neither is required to make or use the antigen-binding molecule of Invention IV. Although the polypeptide of Invention II can be used to obtain the antigen-binding molecule of

Art Unit: 1647

Invention IV it can also be used in materially different methods, such as in various diagnostic (e.g., isolating receptors), or therapeutic methods.

5. Inventions III and V are related as product and processes of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the processes for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the product as claimed can be used in a materially different process of using that product. The antigen-binding molecule of Invention III can be used to isolate receptors.

6. Inventions IV and VI are related as product and processes of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the processes for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the product as claimed can be used in a materially different process of using that product. The antigen-binding molecule of Invention IV can be used to isolate receptors.

7. Inventions VII and I are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the isolated polypeptide of Invention I could be made using materially different processes such as isolation from natural sources or chemical synthesis.

Art Unit: 1647

8. Inventions VIII and II are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the isolated polypeptide of Invention II could be made using materially different processes such as isolation from natural sources or chemical synthesis.

9. Inventions I and each of V, VI, and VIII are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions of Inventions I and each of V, VI, and VIII are unrelated product and methods, wherein each is not required, one for another. For example, the claimed methods of Inventions V, VI, and VIII do not recite the use or production of the polypeptide of Invention I.

10. Inventions II and each of V, VI, and VII are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions of Inventions II and each of V, VI, and VII are unrelated product and methods, wherein each is not required, one for another. For example, the claimed methods of Inventions V, VI, and VII do not recite the use or production of the polypeptide of Invention II.

11. Inventions III and each of VI, VII, and VIII are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different

Art Unit: 1647

modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01).

In the instant case the different inventions of Inventions III and each of VI, VII, and VIII are unrelated product and methods, wherein each is not required, one for another. For example, the claimed methods of Inventions VI, VII, and VIII do not recite the use or production of the antigen-binding molecule of Invention III.

12. Inventions IV and each of V, VII, and VIII are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01).

In the instant case the different inventions of Inventions IV and each of V, VII, and VIII are unrelated product and methods, wherein each is not required, one for another. For example, the claimed methods of Inventions V, VII, and VIII do not recite the use or production of the antigen-binding molecule of Invention IV.

13. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

14. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, separate search requirements, and/or different classification, restriction for examination purposes as indicated is proper.

15. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the

Application/Control Number: 10/021,571

Page 8

Art Unit: 1647

application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christopher Nichols, Ph.D. whose telephone number is 703-305-3955. The examiner can normally be reached on Monday through Friday, 8:30AM to 5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz, Ph.D. can be reached on 703-308-4623. The fax phone numbers for the organization where this application or proceeding is assigned are 703-872-9306 for regular communications and 703-872-9307 for After Final communications. The fax phone numbers for the customer service center is 703-872-9305.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

CJN
November 19th, 2002

Elizabeth C. Semmer